Balanced Portfolio Recommendation: Trim Take Profit – CSL Ltd (CSL)
CSL continues to rally @ $281. Original position was 8% allocation. Today trim another 2% to take down to 4% allocation.
Balanced Portfolio
Balanced Portfolio Recommendations: Buy Telix Phama(TLX)
Add Telix Pharma (TLX) in our balanced portfolio, capitalizing on Telix’s innovative cancer treatment advancements and market potential.
Balanced Portfolio Recommendation: Trim Short Nasdaq (SNAS)
The Nasdaq hedge is unlikely to work over the short-term as the thesis of the rate hiking cycle being finished, combined with the 70% occurrence of a “Christmas Rally”
Balanced Portfolio Recommendation: Buy Pilbara Minerals Ltd (PLS)
Investing 1% of our portfolio allocation in PLS presents a compelling opportunity. PLS stands as the most shorted stock on the ASX, with a substantial 20.45% short interest. This indicates potential for a short squeeze, which could lead to a rapid price increase.
Balanced Portfolio Recommendation: Buy Uranium URNM ETF
URNM provides exposure to leading global companies involved in the mining, exploration, development and production of uranium, modern nuclear energy, or that hold physical uranium or uranium royalties
Balanced Portfolio Recommendation: SELL Take Profit – Ventia (VNT)
Sell 2.5% holding in Ventia services for 10% profit
Balanced Portfolio Recommendation: Trim Take Profit – CSL Ltd (CSL)
The CSL position that we put on initially is now 10% in the money. We are looking to trim 2% or 1/4 of our position to take a profit.
Balanced Portfolio Recommendation: Sell – Macquarie Group Ltd (MQG)
Macquarie Bank is set to announce earnings, consistently demonstrating a remarkable record of exceeding expectations. MQG is a cornerstone in our portfolios, showcasing reliable performance. We advise purchasing a 2%-4% allocation of MQG shares on Thursday, anticipating a potential gap-up at Friday’s market open, following the release of positive updates.
Balanced Portfolio Recommendation: Buy IPD Group Ltd (IPG)
Shifting from Ventia to IPD, leveraging Ventia’s 9% return for IPD’s undervalued potential, aligns with our strategy for value-driven, defensive investment opportunities.
Strategy Update: Switch 2% of Neuren Pharma (NEU) to Telix Phama(TLX)
Switching from Neuren Pharma (NEU) to Telix Pharma (TLX) in our balanced portfolio, capitalizing on Telix’s innovative cancer treatment advancements and market potential.
Strategy Update: Agriculture Reporting Season – Switch 2% of NUF to GNC
The final leg of our agricultural earnings season strategy, we are recommending a switching the 2% allocation in Nufarm to GrainCorp